Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): Efficacy results

Category Primary study
JournalBreast
Year 2011
This article has no abstract
Epistemonikos ID: a47f5a8510d08f84d4491097cf92b850d0520b55
First added on: Feb 07, 2025